| Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2 J Nangalia, CE Massie, EJ Baxter, FL Nice, G Gundem, DC Wedge, ... New England Journal of Medicine 369 (25), 2391-2405, 2013 | 2127 | 2013 |
| Pan-cancer analysis of whole genomes Nature 578 (7793), 82-93, 2020 | 1695* | 2020 |
| Effect of mutation order on myeloproliferative neoplasms CA Ortmann, DG Kent, J Nangalia, Y Silber, DC Wedge, J Grinfeld, ... New England Journal of Medicine 372 (7), 601-612, 2015 | 595 | 2015 |
| Classification and personalized prognosis in myeloproliferative neoplasms J Grinfeld, J Nangalia, EJ Baxter, DC Wedge, N Angelopoulos, R Cantrill, ... New England Journal of Medicine 379 (15), 1416-1430, 2018 | 561 | 2018 |
| Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer YS Ju, LB Alexandrov, M Gerstung, I Martincorena, S Nik-Zainal, ... elife 3, e02935, 2014 | 397 | 2014 |
| The mutational landscape of normal human endometrial epithelium L Moore, D Leongamornlert, THH Coorens, MA Sanders, P Ellis, ... Nature 580 (7805), 640-646, 2020 | 395 | 2020 |
| Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial RA Mesa, AM Vannucchi, A Mead, M Egyed, A Szoke, A Suvorov, ... The Lancet Haematology 4 (5), e225-e236, 2017 | 283 | 2017 |
| Extensive heterogeneity in somatic mutation and selection in the human bladder ARJ Lawson, F Abascal, THH Coorens, Y Hooks, L O’Neill, C Latimer, ... Science 370 (6512), 75-82, 2020 | 220 | 2020 |
| Clonal dynamics of haematopoiesis across the human lifespan E Mitchell, M Spencer Chapman, N Williams, KJ Dawson, N Mende, ... Nature 606 (7913), 343-350, 2022 | 199 | 2022 |
| Myeloproliferative neoplasms: from origins to outcomes J Nangalia, AR Green Hematology 2014, the American Society of Hematology Education Program Book …, 2017 | 196 | 2017 |
| Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms W Tapper, AV Jones, R Kralovics, AS Harutyunyan, K Zoi, W Leung, ... Nature communications 6 (1), 6691, 2015 | 186 | 2015 |
| The longitudinal dynamics and natural history of clonal haematopoiesis MA Fabre, JG de Almeida, E Fiorillo, E Mitchell, A Damaskou, J Rak, ... Nature 606 (7913), 335-342, 2022 | 185 | 2022 |
| Life histories of myeloproliferative neoplasms inferred from phylogenies N Williams, J Lee, E Mitchell, L Moore, EJ Baxter, J Hewinson, KJ Dawson, ... Nature 602 (7895), 162-168, 2022 | 168 | 2022 |
| Inactivating CUX1 mutations promote tumorigenesis CC Wong, I Martincorena, AG Rust, M Rashid, C Alifrangis, ... Nature genetics 46 (1), 33-38, 2014 | 160 | 2014 |
| A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline M McMullin, C Harrison, S Ali, C Cargo, F Chen, J Ewing, M Garg, ... British journal of haematology 184 (2), 2018 | 152 | 2018 |
| DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype J Nangalia, FL Nice, DC Wedge, AL Godfrey, J Grinfeld, C Thakker, ... Haematologica 100 (11), e438, 2015 | 126 | 2015 |
| The evolving genomic landscape of myeloproliferative neoplasms J Nangalia, TR Green Hematology 2014, the American Society of Hematology Education Program Book …, 2014 | 116 | 2014 |
| Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms J Grinfeld, J Nangalia, AR Green Haematologica 102 (1), 7, 2017 | 114 | 2017 |
| Lineage tracing of human development through somatic mutations M Spencer Chapman, AM Ranzoni, B Myers, N Williams, THH Coorens, ... Nature 595 (7865), 85-90, 2021 | 104 | 2021 |
| A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline MFF McMullin, AJ Mead, S Ali, C Cargo, F Chen, J Ewing, M Garg, ... British journal of haematology 184 (2), 161, 2019 | 94 | 2019 |
